ReviewFrontiers in oncology2014
Effects of epithelial to mesenchymal transition on T cell targeting of melanoma cells.
Review in Frontiers in oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 36 citations in OpenAlex.
- The role of notch signaling in tumor angiogenesis in hematological malignancies.Frontiers in oncology · 2026Review
- Article
- Crosstalk between Immune Checkpoint Modulators, Metabolic Reprogramming and Cellular Plasticity in Triple-Negative Breast Cancer.Current oncology (Toronto, Ont.) · 2022Review
- Modeling the effects of EMT-immune dynamics on carcinoma disease progression.Communications biology · 2021Article
- Ropporin-1 and 1B Are Widely Expressed in Human Melanoma and Evoke Strong Humoral Immune Responses.Cancers · 2021Article
- Long non-coding RNA TINCR suppresses metastatic melanoma dissemination by preventing ATF4 translation.EMBO reports · 2021Article
- TAM kinase inhibition and immune checkpoint blockade- a winning combination in cancer treatment?Expert opinion on therapeutic targets · 2021Review
- Low-Dose Albendazole Inhibits Epithelial-Mesenchymal Transition of Melanoma Cells by Enhancing Phosphorylated GSK-3Journal of oncology · 2021Article
- Cellular Reprogramming-A Model for Melanoma Cellular Plasticity.International journal of molecular sciences · 2020Review
- Analysis of DNA methylation patterns in the tumor immune microenvironment of metastatic melanoma.Molecular oncology · 2020Article
- Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy.Lung cancer (Amsterdam, Netherlands) · 2020Article
- The Vicious Cross-Talk between Tumor Cells with an EMT Phenotype and Cells of the Immune System.Cells · 2019Review
- Epithelial-Mesenchymal Transition in Skin Cancers: A Review.Analytical cellular pathology (Amsterdam) · 2019Review
- Epithelial-mesenchymal transition (EMT) signature is inversely associated with T-cell infiltration in non-small cell lung cancer (NSCLC).Scientific reports · 2018Article
- Cell death-based treatments of melanoma:conventional treatments and new therapeutic strategies.Cell death & disease · 2018Review
- Concepts Collide: Genomic, Immune, and Microbial Influences on the Tumor Microenvironment and Response to Cancer Therapy.Frontiers in immunology · 2018Review
- The Role of Actin Dynamics and Actin-Binding Proteins Expression in Epithelial-to-Mesenchymal Transition and Its Association with Cancer Progression and Evaluation of Possible Therapeutic Targets.BioMed research international · 2018Review
- Article
- Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack.Cancer biology & therapy · 2017Review
- Immunotherapy resistance: the answers lie ahead - not in front - of us.Journal for immunotherapy of cancer · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melanoma cells can switch phenotype in a manner similar to epithelial to mesenchymal transition (EMT). In this perspective article, we address the effects of such phenotype switching on T cell targeting of tumor cells. During the EMT-like switch in phenotype, a concomitant change in expression of multiple tumor antigens occurs. Melanoma cells undergoing EMT escape from killing by T cells specific for antigens whose expression is downregulated by this process. We discuss melanoma antigens whose expression is influenced by EMT. We assess the effect of changes in the expressed tumor antigen repertoire on T-cell mediated tumor recognition and killing. In addition to escape from T cell immunity via changes in antigen expression, mesenchymal-like melanoma cells are generally more resistant to classical chemotherapy and radiotherapy. However, we demonstrate that when targeting antigens whose expression is unaltered during EMT, the capacity of T cells to kill melanoma cell lines in vitro is not influenced by their phenotype. When considering immune therapies such as cancer vaccination, these data suggest escape from T cell killing due to phenotype switching in melanoma could potentially be avoided by careful selection of target antigen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.